Abstract
BackgroundICIs (PD-1 inhibitors, PDL-1 inhibitors, CTLA-4 inhibitors) are increasingly used to treat various malignancies. The percentage of cancer patients in the US who may benefit from ICIs has increased from...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have